April 29, 2020

MegaSporeBiotic™ and Triglyceride Levels

MegaSporeBiotic™ and Triglyceride Levels

Press Release

April 29, 2020

Microbiome Labs announces their recent study, Efficacy of Spore-Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial, has just been published in Integrative Medicine: A Clinician’s Journal.

Approximately 1/3 of the population has elevated triglyceride levels (> 150 mg/dL) in the bloodstream, or hypertriglyceridemia (HT). In addition to cholesterol levels like LDL and HDL, elevated levels of triglycerides are also commonly used as indicators for heart disease risk.

Due to the metabolic functions of the gut microbiome, an imbalance of gut bacteria (gut dysbiosis) can increase serum triglycerides by increasing intestinal permeability and allowing for bacterial endotoxin translocation into circulation.

Finally, excessive intake of certain dietary fat stimulates triglyceride production in the liver. As triglycerides circulate the body, they can contribute to plaque formation in arteries, fatty build-up around the liver, and systemic inflammation.


This study examined the effects of gut microbiota modulation, using MegaSporeBiotic™, in reducing serum triglycerides. Researchers recruited 80 participants with non-fasting triglyceride levels greater than 150 mg/dL to complete the study.

The average baseline triglyceride levels were 207 mg/dL. Participants were randomly divided into 2 groups. The treatment group received 2 capsules of MegaSporeBiotic™ once daily, which was taken in the morning. The control group received a placebo pill containing rice flour. Triglyceride levels were measured at baseline, 6 weeks, and 12 weeks of the experiment.

Results indicated that non-fasting triglyceride levels dropped by 25 percent in just 6 weeks and 38 percent after 12 weeks of probiotic supplementation. This study highlights the efficacy of MegaSporeBiotic™ in reducing serum triglyceride levels.


This study is the second publication on MegaSporeBiotic™ that demonstrates a significant reduction in serum triglyceride levels. Serum triglycerides are a critical end-point for a probiotic, as they illustrate the ability of the probiotic to conduct several critical metabolic functions in the microbiome.

Bacillus spore-based probiotics are gaining popularity due to their safety, survivability, and capacity to modulate the gut microbiome. Research continues to highlight the role of MegaSporeBiotic™ in supporting human health outcomes, and we are honored to have your support as we continue to promote the importance of clinical research in the supplement industry.

Click here to download the full study.


Campbell AW, Sinatra D, Zhang Z, et al. Efficacy of Spore Forming Bacilli Supplementation in Patients with Mild to Moderate Elevation of Triglycerides: A 12 week, Randomized, Double-Blind, Placebo Controlled Trial. Integrative Medicine. 2020;19(2):18-23.

Categorized Under